SAHA and PJ 1548,a Novel Tyrosine Kinase Inhibitor Synergistically Induce Apoptosis in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

摘要：

　　Limited treatment options are available for chronic myeloid leukemia (CML) patients who develop imatinib mesylate resistance particularly in patients with gatekeep mutant Bcr-Abl such as T3151.Compound PJ 1548 was originally designed and synthesized against T3151 Bcr-Abl in our lab.The kinase assay showed that it blocked multiple tyrosine kinases including both wild-type as well as T3151 Bcr-Abl.Despite so,the lesson taken in the clinical application of imatinib and the second-generation of small molecule inhibitors (nilotinib and dasatinib) hint that resistance may arise.

作者: Qiangui Bu Ke Ding Jingxuan Pan

作者单位: Department of Pathophysiology,Zhongshan School of Medicine,Sun Yat-sen University,Guangzhou,China Key Laboratory of Regenerative Biology and Institute of Chemical Biology,Guangzhou Institute of Biom

会议类型: 国内会议

会议名称: 2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会

会议地点: 深圳

会议语种:英文

页码: 402-402

在线出版日期: 2012-07-13（万方平台首次上网日期，不代表论文的发表时间）